Dr. DeVincenzo Studies Respiratory Syncytial Virus (RSV)
John DeVincenzo, MD, of the department of pediatrics at the University of Tennessee Health Science Center in Memphis, Tenn., said the current double blind, placebo-controlled phase 2 study aimed to evaluate ALS‑008176, an oral nucleoside analogue that causes nascent RNA chain-termination, thereby inhibiting RSV replication.

